-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab's Rina-S improves survival in Phase 3 ovarian cancer trial

PUBT·10/23/2026 15:55:42
Listen to the news
Genmab's Rina-S improves survival in Phase 3 ovarian cancer trial
  • Genmab’s investigational Rina-S improved progression-free survival versus chemotherapy in the Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer.
  • Overall survival also improved significantly; benefits were clinically meaningful across both trial analysis populations.
  • No new safety signals or unexpected safety concerns emerged.
  • Results will be submitted for presentation at a future medical meeting, with regulatory discussions planned worldwide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231155PRIMZONEFULLFEED1001279615) on October 23, 2026, and is solely responsible for the information contained therein.